SBFM
NASDAQSunshine Biopharma Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$1.00-0.26 (-20.95%)
2026-01-212026-04-24
News · 26 weeks120%
2025-11-022026-04-26
Mix1090d
- SEC Filings5(50%)
- Other3(30%)
- Market1(10%)
- Insider1(10%)
Latest news
25 items- INSIDERSEC Form 4 filed by Natan David4 - Sunshine Biopharma Inc. (0001402328) (Issuer)
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior YearFORT LAUDERDALE, FL / ACCESS Newswire / April 6, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("Sunshine Biopharma" or the "Company"), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the filing of its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025.2025 HighlightsRevenue of $36.3 million, representing a 4.1% increase compared to 2024.$2.46 million in gross proceeds raised through a registered direct offering to support expansion of sales operations.Nine new generic prescription drugs launched, expanding the Company's portfolio in oncology, cardiovascular health, central
- SECSEC Form 10-K filed by Sunshine Biopharma Inc.10-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form NT 10-K filed by Sunshine Biopharma Inc.NT 10-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form DEF 14C filed by Sunshine Biopharma Inc.DEF 14C - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form PRE 14C filed by Sunshine Biopharma Inc.PRE 14C - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Leadership Update8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form 10-Q filed by Sunshine Biopharma Inc.10-Q - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma (NASDAQ:SBFM) is quickly establishing which side of that line it's on. After scoring another major regulatory win, that position certainly isn't one of many in the crowd. On Tuesday, the company announced that it had secured Health Canada authorization to commercialize domperidone through its Nora Pharma subsidiary, a milestone that not only expands its commercial reach but also validates its growing track record of revenue-generating execution.It's a potentially enormous win, particularly for a microcap biotech trading with a market cap under $10 mill
- NEWSSunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related NauseaFORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company focused on innovative and affordable healthcare solutions, today announced that its wholly owned subsidiary, Nora Pharma Inc., has received approval from Health Canada, the Canadian equivalent to the FDA, for the commercialization of Domperidone, a prescription medication used to relieve nausea and vomiting and to enhance gastrointestinal motility.Domperidone is often used for chemotherapy-induced nausea and vomiting, especially when patients cannot tolerate other antiemetics which may cause extrapyramidal side effects. Domperidone works by blocki
- SECSEC Form DEFA14A filed by Sunshine Biopharma Inc.DEFA14A - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form DEF 14A filed by Sunshine Biopharma Inc.DEF 14A - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Launches STD, Acne and Lyme Disease Therapy DoxycyclineFORT LAUDERDALE, FL, QC / ACCESS Newswire / October 20, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company focused on innovative and affordable healthcare solutions, today announced the commercial launch of generic Doxycycline in Canada. This strategic move strengthens the Company's footprint in the Canadian growing antibiotic sector. Doxycycline is now available to pharmacies, hospitals and healthcare providers nationwide.Doxycycline is a broad-spectrum antibiotic used to treat respiratory tract infections, urinary tract infections, sexually transmitted diseases, acne, and tick-borne illnesses such as Lyme disease. With high oral bioavailability a
- NEWSSunshine Biopharma Launches Cholesterol Fighting Medicine PravastatinFORT LAUDERDALE, FL, QC / ACCESS Newswire / October 16, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched Pravastatin, a generic prescription drug in the therapeutic class of Lipid Metabolism Regulators.Pravastatin is a generic version of Pravachol®. Pravastatin is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood. This helps prevent heart attacks, strokes, and other serious cardiovascular
- NEWSSunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma (NASDAQ:SBFM) is quietly engineering a flywheel model for biotech. Not a flashy one that spins fast and burns energy and cash quickly. A lean machine that builds speed-step by step-compounding every strategic win so that the next push gets more than easier; it's immediately accretive.Sunshine started where most microcaps stay: generics. Through its Nora Pharma arm, it's built a catalog of reliable, repeatable therapeutic products in Canada. It's not glamorous, but it's real revenue. Launches like gabapentin and others expand the footprint, feed cash flow, and build legitimacy. That's the first spin of the wheel - e
- NEWSSunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma (NASDAQ:SBFM) is the kind of company that keeps the market honest. On paper, it's small, barely a rounding error next to the giants of biotech. But size isn't the story here. Execution is. Sunshine has spent the past year building an engine that's starting to hum across multiple fronts: generics, biosimilars, mRNA cancer therapies, and antiviral research. And in the process, it's doing what small companies rarely do well: scale with discipline.In Canada, Sunshine's Nora Pharma subsidiary has been quietly expanding its generics portfolio, stacking products that feed real, repeatable revenue. The launch of gabapentin
- NEWSSunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury ResilienceFORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced its Board of Directors has formally approved a strategic investment of $5 million in Bitcoin (BTC) as a strategic reserve asset. This move aligns with Sunshine Biopharma's broader strategy to strengthen its financial foundation while advancing its pipeline of generic prescription drugs and proprietary mRNA-based cancer therapies and antiviral drug candidates.The Company's Bitcoin investment of $5 million will be execu
- NEWSSunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus InfectionsFORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has developed a new series of orally active, non-covalent protease inhibitors with dose-dependent antiviral activity in mice infected with SARS Coronavirus (SARS-CoV-2). This work was carried out at the University of Arizona as part of an ongoing collaboration between the Company and the University.Coronavirus remains a formidable global health threat, not only due to its ability to cause severe illness (particularly in
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form EFFECT filed by Sunshine Biopharma Inc.EFFECT - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form 10-Q filed by Sunshine Biopharma Inc.10-Q - Sunshine Biopharma Inc. (0001402328) (Filer)